Hyponatremia in Congestive Heart Failure (CHF): Harnessing the Horse with Tolvaptan

Abstract

Hyponatremia in Congestive Heart Failure (CHF) is a complex and ominous clinical entity that transcends simple electrolyte imbalance. It serves as a profound indicator of advanced neurohormonal derangement and stands as one of the most reliable predictors of morbidity and mortality in the heart failure population [12, 20]. While traditional loop diuretics remain the cornerstone of decongestion, they frequently exacerbate hyponatremia by causing natriuresis and further activating the renin-angiotensin-aldosterone system (RAAS), leading to a state of "diuretic resistance" [5, 15]. Tolvaptan—an oral, selective vasopressin V_2-receptor antagonist—offers a physiologically targeted alternative. By inducing "aquaresis" (the excretion of solute-free water) rather than natriuresis, tolvaptan allows clinicians to "harness" the runaway vasopressin response [7, 18]. This article provides a comprehensive exploration of the pathophysiology of hypervolemic hyponatremia, the foundational clinical evidence supporting vaptan therapy, and a structured, safe approach to managing these high-risk patients